Product logins

Find logins to all Clarivate products below.

home   •  Research Reports  •  DRG Market Assessment Reports

Sjogren’s Syndrome | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2019

Login to access report north_east
Contact sales account_box

SS is a progressive autoimmune disease characterized by chronic inflammation and lymphocytic infiltration of the exocrine glands that may occur alone (primary SS) or with a comorbid autoimmune condition (secondary SS). Symptomatic therapies to treat dry eyes, dry mouth, or specific extraglandular manifestations are the cornerstone of disease management. Systemic manifestations are most often treated with hydroxychloroquine or, in severe cases, systemic immunomodulators (e.g., azathioprine, methotrexate). Dry eye in SS is treated with eye drops (e.g., Novartis’s Xiidra); dry mouth is treated with artificial saliva or muscarinic receptor agonists. Therapies with disease-modifying potential are in development for SS, targeting key pathways believed to drive pathological processes in the disease. These putative disease-modifying therapies have the potential to transform the management of SS, although SS is an indication in which success has historically proven to be a challenge.

QUESTIONS ANSWERED

  • How large is the SS population, and how will its size change over time?
  • How is SS currently managed? Which drugs are the most important, and what drives their use?
  • Which unfulfilled clinical needs are the most pressing?
  • Which pipeline products are the most promising (e.g., Novartis’s iscalimab), and what sales might they garner in the SS market? What therapies of note are progressing in earlier phases?
  • What are the drivers and constraints in the SS market, and how will the market evolve through 2028?

CONTENT HIGHLIGHTS

  • Geographies: United States and EU5
  • Primary Research: Six country-specific interviews with thought-leading rheumatologists supported by survey data collected for this study
  • Epidemiology: Diagnosed and drug-treated prevalent cases of SS by country, prevalence of primary SS
  • Forecast: Drug-level sales and patient share of key SS therapies in 2018 and 2028
  • Emerging Therapies: Phase II: 9 drugs; coverage of select preclinical and Phase I products
Contact sales account_box
Login to access report north_east

Related Market Assessment Reports

Report
Hepatitis B Virus – Geographic Focus: China – China In-Depth – Hepatitis B Virus
HBV is a major public health burden in China, with chronically infected individuals at a significantly increased risk of developing hepatic cirrhosis and hepatocellular carcinoma. Current treatment…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Current Treatment: Physician Insights – B-Cell Non-Hodgkin’s Lymphoma (US)
Non-Hodgkin’s lymphoma (NHL) represents a diverse group of hematological malignancies broadly classified into indolent and aggressive subtypes. Patients with aggressive NHL—diffuse large B-cell…
north_east
Report
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia – Current Treatment – Treatment Sequencing – B-Cell Non-Hodgkin’s Lymphoma (US)
Key benefits and usesPinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand who to position against…
north_east
Report
Psoriasis – Unmet Need – Unmet Need – Moderate to Severe Psoriasis (US/EU)
Topical therapies are the backbone of psoriasis management; however, they are often inadequate for patients with moderate to severe disease, who typically require systemic treatment. While…
north_east
Report
Non-Small-Cell Lung Cancer – Unmet Need – Unmet Need – Metastatic NSCLC without driver mutations (US EU)
First-line treatment for non-small-cell lung cancer (NSCLC) patients without driver mutations typically includes an immune checkpoint inhibitor, with or without platinum-based chemotherapy,…
north_east

Follow us

Contact us

Sales enquiries north_east
Customer service north_east
Support north_east